At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk
In Brief
A Phase 4 clinical trial evaluating Depot medroxyprogesterone acetate (DMPA), Etonogestrel implant (Eng-Implant), and 2 other interventions for HIV and Contraception. Completed, enrolled 59 participants across 4 sites.
Detailed Summary
This is a prospective cohort study focusing on HIV negative women. The investigators want to learn how the contraceptive methods of depot medroxyprogesterone acetate (DMPA), etonogestrel implant (Eng-Implant), levonorgestrel intrauterine device (Lng-IUD) and the ParaGard® T 380A Intrauterine Copper Contraceptive impact the vaginal immune environment.
Study Details
Timeline
Interventions
DMPA will be administered every 12 weeks at the standard dose of 150 mg IM, beginning from week 3 of study enrollment and repeated at week 15.
A standard nexplanon rod implant will be placed at study week 3 by a trained clinician.
A standard Mirena IUD will be placed at study week 3 by a trained clinician.
A standard ParaGuard IUD will be placed at study week 3 by a trained clinician.